Please select the option that best describes you:
How would you approach treatment for a pre-menopausal patient with PR-positive, ER-negative, HER2-negative cT1c N1 breast cancer?
Should these cancers be treated like hormone positive breast cancer or triple negative breast cancer?
She is pre menopausal with cT1c grade 2 disease and N1 (biopsy proven) involving one node in the axilla.
Answer from: Medical Oncologist at Academic Institution
The prevalence of ER- PR+ HER2- breast cancer is relatively low and probably ranges from about 0-8%, with concerns about technical errors in HR status determination by IHC often being expressed in this instance. Because of this, I would consider repeat receptor testing at some point (an additional b...
Sign in or Register to read more